The FDA is preparing to decide on Moderna's mRNA-based flu shot, which could become the first of its kind on the market. According to NPR, the ruling is expected to reverberate throughout the biotech industry. The report notes the underlying mRNA technology is an approach Robert F. Kennedy Jr. has questioned.
Key facts
- The FDA is poised to decide on Moderna's mRNA-based flu shot.
- If approved, it could be the first mRNA flu shot to reach the market.
- NPR reports the decision is expected to reverberate throughout the biotech industry.
- NPR notes the underlying mRNA technology has been questioned by Robert F. Kennedy Jr.
The U.S. Food and Drug Administration is poised to render a decision on Moderna’s mRNA-based flu shot, according to NPR. If cleared, the vaccine could become the first of its kind to reach the market.
NPR reports that the pending decision is expected to reverberate throughout the biotech industry.
The report notes that the mRNA technology at the centre of the decision is an approach that Robert F. Kennedy Jr. has questioned.
Why it matters
According to NPR, an FDA decision on Moderna's mRNA flu shot could bring the first vaccine of its kind to market and is expected to reverberate throughout the biotech industry.
Frequently asked questions
What is the FDA deciding on?
According to NPR, the FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market.
Why does this decision matter for the industry?
NPR reports the decision is expected to reverberate throughout the biotech industry.
Who has questioned the technology?
The mRNA technology behind the shot is an approach that RFK Jr. has questioned, according to NPR.